Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study
Heinz Gisslinger(Medical University of Vienna), Richard Greil(Paracelsus Medical University), Michael Zoerer(AOP Orphan (Austria)), Pavla Kadlecová, Dominik Wolf(Universität Innsbruck), Ella Willenbacher(Innsbruck Medical University), Alexander Egle(Paracelsus Medical University), Ernst Schloegl(Hanusch Hospital), Oleh Zagrijtschuk(AOP Orphan (Austria)), Veronika Buxhofer‐Ausch(Johannes Kepler University of Linz), Christoph Klade(Intercell (Austria)), Bettina Gisslinger(Medical University of Vienna), Thomas Melchardt(Paracelsus Medical University), Karin Strecker(Donauspital), Josef Thaler(Thrombolysis in Myocardial Infarction Study Group), Sonja Burgstaller(Klinikum Wels-Grieskirchen), Guenther Gastl(Innsbruck Medical University), Róbert Královics(Medical University of Vienna)
Cited by 0
Related Papers
A Gain-of-Function Mutation of <i>JAK2</i> in Myeloproliferative Disorders
|New England Journal of Medicine|2005|3.5k
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
|Journal of Clinical Oncology|2011|540
Bim is a suppressor of Myc-induced mouse B cell leukemia
|Proceedings of the National Academy of Sciences|2004|482
Erythropoietin Treatment of Anemia Associated with Multiple Myeloma
|New England Journal of Medicine|1990|450